Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flurbiprofen patch clinical endpoint bioequivalence study in knee osteoarthritis pain
CTR20254338Phase 3Terminated
- Sponsor
- Conba Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of flurbiprofen in knee osteoarthritis (OA) (3 arms), sponsored by Conba Pharmaceutical. Primary endpoint: Change from baseline in walking pain VAS at Week 2. Started Nov 2025; status: terminated.
02
Drugs
flurbiprofen
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on CTR20254338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254338.